Evidence map›Paper›PMID 24407959›Full record

ArticleProtein science : a publication of the Protein Society2014

Pentraxins and IgA share a binding hot-spot on FcαRI.

Jinghua Lu, Kristopher D Marjon, Carolyn Mold, Lorraine Marnell, Terry W Du Clos, Peter Sun

Open access · bronzeAbstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Isotype selection for antibody-based cancer therapy.Clinical and experimental immunology · 2021
    Review
  3. Article
  4. Review
  5. Review
  6. IgA: Structure, Function, and Developability.Antibodies (Basel, Switzerland) · 2019
    Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Jinghua LuStructural Immunology Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, 20852.
Kristopher D Marjon
Carolyn Mold
Lorraine Marnell
Terry W Du Clos
Peter Sun
University of New Mexico · USNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USRaymond G. Murphy VA Medical Center · US

Funding

Structural Mechanism of B cell receptor and complement activationZIAAI000853 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SUN, PETER D. · 2009 to 2022
$5.3M
Biology of Infectious Diseases &InflammationT32AI007538 · NIAID · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Michelle A Ozbun · 1998 to 2026
$5.2M
C-Reactive Protein Binding to CD89: Structure and FunctionR21AI085414 · NIAID · BIOMEDICAL RESEARCH INSTITUTE OF NEW MEX · PI DU CLOS, TERRY W · 2010 to 2011
$299k
C-reactive protein supresses the immune system through Fc gamma receptorsF31AI080178 · NIAID · BIOMEDICAL RESEARCH INSTITUTE OF NEW MEX · PI MARJON, KRISTOPHER DAVID · 2009 to 2010
$57k
Intramural NIH HHSNIAID NIH HHS F31AI080178NIAID NIH HHS R21AI085414NIAID NIH HHS T32 AI007538
6 · The paper itself

Abstract

The pentraxins, C-reactive protein (CRP), and serum amyloid P component (SAP) have previously been shown to function as innate opsonins through interactions with Fcγ receptors. The molecular details of these interactions were elucidated by the crystal structure of SAP in complex with FcγRIIA. More recently, pentraxins were shown to bind and activate FcαRI (CD89), the receptor for IgA. Here, we used mutations of the receptor based on a docking model to further examine pentraxin recognition by FcαRI. The solution binding of pentraxins to six FcαRI alanine cluster mutants revealed that mutations Y35A and R82A, on the C-and F-strands of the D1 domain, respectively, markedly reduced receptor binding to CRP and SAP. These residues are in the IgA-binding site of the receptor, and thus, significantly affected receptor binding to IgA. The shared pentraxin and IgA-binding site on FcαRI is further supported by the results of a solution binding competition assay. In addition to the IgA-binding site, pentraxins appear to interact with a broader region of the receptor as the mutation in the C'-strand (R48A/E49A) enhanced pentraxin binding. Unlike Fcγ receptors, the H129A/I130A and R178A mutations on the BC- and FG-loops of D2 domain, respectively, had little effect on FcαRI binding to the pentraxins. In conclusion, our data suggest that the pentraxins recognize a similar site on FcαRI as IgA.

Indexed as

Antigens, CDBinding SitesC-Reactive ProteinHumansImmunoglobulin AMutationNeutrophilsReceptors, FcSerum Amyloid P-ComponentAntigens, CDC-Reactive ProteinFc(alpha) receptorImmunoglobulin AReceptors, FcSerum Amyloid P-Componentcompetitionsite-directed mutagenesissurface plasmon resonance

Identifiers

PMID24407959
PMCPMC3970889
OpenAlexW1541923252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.